ISCP e-Newsletter - December 2025
Closing 2025 Together: ISCP Highlights, Key Learnings & a Look Ahead to 2026
As 2025 draws to a close, we are delighted to share with you this final edition of the ISCP Newsletter for the year — a reflection on a remarkable 12 months of scientific advancement, education, and global engagement.
This year has seen meaningful strides in cardiovascular pharmacotherapy, delivered through our in-person and digital platforms alike. From major congresses to the growing library of on-demand educational content, ISCP has continued to provide high-impact, practical learning for clinicians and researchers around the world.
In this issue, you’ll find highlights from our 30th Annual Scientific Meeting in Oviedo, access information for our most recent webinars, updates on the European Cardiology Review (our official journal), and exciting events for 2026. We hope this newsletter inspires you to continue engaging with ISCP’s educational and scientific initiatives and to join us in shaping the future of cardiovascular pharmacotherapy.
Editors: Lourdes Marenco & Lisa Demos
President’s Section
Dear ISCP friends,
As we approach the end of 2025, I would like to express my deepest gratitude for having had the honour to serve as President of ISCP. This year has been particularly meaningful, and I am proud of what we have achieved together.
Our 30th Annual Scientific Meeting, held on 25–26 September in Oviedo, Spain, was a stunning success. The meeting — the second time our Society has convened in Spain — drew global participation and brought together international experts and members from around the world.
Thanks to the active contributions and engagement of our community, the congress offered a rich scientific programme covering coronary disease, heart failure, arrhythmias, hypertension, diabetes, cardio-oncology and cutting-edge pharmacotherapy innovations.
Beyond the Annual Meeting, ISCP continued to deliver educational and scientific value throughout 2025:
We offered a series of live webinars and online learning modules — for instance, sessions on anticoagulation stewardship, management of iron deficiency in heart failure, real-world evidence for atrial fibrillation and VTE, Lp(a) challenges in primary prevention, to name a few.
Our official journal, the ECR, published its latest volume with open-access articles, providing expert reviews and insights into the evolving landscape of cardiovascular pharmacotherapy.
We continued to support and endorse specialised educational programmes and workshops — including international events in Austria and Romania, as well as other endorsed regional cardiology congresses and meetings.
These accomplishments reflect the dedication, expertise and collaborative spirit that define ISCP. The success of our 2025 activities has strengthened our global network and reinforced our shared mission to advance cardiovascular pharmacotherapy for the benefit of patients worldwide.
As I step down from the presidency, I would like to thank each one of you for your support, enthusiasm and active participation. I leave with full confidence that ISCP — under new leadership — will continue to grow, innovate and make meaningful impact in the years ahead.
I wish you and your loved ones a joyful holiday season and a healthy, inspiring, and prosperous New Year. May 2026 bring new opportunities for knowledge, collaboration and progress for us all.
With warmest regards,
Prof Pablo Avanzas
President ISCP
ISCP News
Highlights from 2025
New Digital Home for ISCP
We are thrilled to announce the launch of our redesigned ISCP Digital Home — a refreshed website that brings improved access to educational resources, upcoming events, webinars, journal content, and member-exclusive materials. This platform will serve as the central hub for all ISCP communications and professional learning. Visit the site anytime to explore resources and stay connected.
Save the Date! ISCP 2026 Singapore
We’re delighted to share that ISCP 2026 will be held in Singapore — returning to Asia for our 31st Annual Scientific Meeting from 3–5 July 2026 at the National Heart Centre Singapore. Mark your calendars, start planning your abstract submissions, and prepare to join us for another outstanding scientific programme.
For registrations and abstract submission details please visit the website.
CALL FOR BIDS – Annual Scientific Sessions 2027 & 2028
ISCP invites proposals from institutions and cities interested in hosting our Annual Scientific Sessions in 2027 and 2028. Full details on submission requirements can be accessed on our website here; we encourage members and affiliates to consider partnering with ISCP to bring these flagship events to your region.
Interested hosts should contact the ISCP Secretariat at [email protected]
Watch All Recordings from ISCP 2025 Oviedo Now!
Couldn’t attend sessions from our 30th Annual Scientific Meeting? Access a comprehensive library of recordings and session highlights from ISCP 2025 Oviedo. Revisit cutting-edge lectures on topics ranging from heart failure to innovative pharmacotherapy and catch up on discussions you might have missed.
Curious to know what our meetings are all about? Watch the highlights from our latest Annual Scientific Meeting held in Oviedo, Spain, through the eyes of our President, keynote speakers, and attendees in this comprehensive recap video.
Watch the Latest Webinars
Missed them live? All recordings available on the ISCP e-Learning hub!
The Lp(a) Challenge in Primary Prevention
ISCP closed the year with the final webinar in the A to Z of Cardiovascular Pharmacotherapy series: “The Lp(a) Challenge in Primary Prevention.” This featured expert insights into the role of Lipoprotein(a) — a genetically determined and often underappreciated driver of ASCVD — practical guidance on who to screen and how to manage risk, and emerging therapeutic avenues in development.
ESC 2025 In Review – An ISCP overview of the must-know updates in CV Pharmacotherapy
Leading experts unpack the most important updates in cardiovascular pharmacotherapy presented at the ESC Congress in Madrid, providing you with a concise and practical overview of the latest breakthrough evidence, guideline updates, and clinical implications for daily practice. Whether or not you attended the congress, this webinar series ensures you stay informed on the key takeaways that matter most for clinicians, pharmacists, researchers, and healthcare professionals worldwide.
ESC 2025 In Review #1 – An ISCP overview of the must-know updates in CV Pharmacotherapy
Our expert international faculty unpack some of the most relevant and practice-changing updates in cardiovascular pharmacotherapy presented at the ESC Congress in Madrid, including hypertension – latest insights from BAX HTN and KARDIA-3; heart failure – results from VICTOR and DAPA ACT HF–TIMI 68; and lipid management and Lp(a) – focused updates and new guideline recommendations. The discussion goes beyond data, exploring clinical implications and therapeutic strategies that can be directly applied in daily practice.
Interested in taking part in ISCP educational programmes?
One of the many benefits of being an ISCP Member is to be considered as a keynote speaker for our live webinars, to be part of the panel as an Expert, or to publish articles such as Expert Opinions on novel information that is relevant to the cardiovascular pharmacotherapy community. If you wish to take an active part in our educational activities, please send an email to [email protected] with your areas of interest to discuss your involvement further.
European Cardiology Review (ECR) – Official ISCP Journal
Our official journal, European Cardiology Review (ECR), continues to offer high-quality, peer-reviewed, open-access content relevant to cardiovascular pharmacotherapy. Volume 20 (2025) includes expert reviews and emerging clinical insights.
Latest articles
Nothing to REFINE Yet
Gheorghe-Andrei Dan
European Cardiology Review 2025;20:e36.
The Role of Frailty in Cardio-oncology and its Challenges
Erkihun Amsalu, Tan Van Nguyen, Harry Klimis, et al.
European Cardiology Review 2025;20:e35.
The Coronary Microcirculation Re-explored: Pathophysiological Insights and Clinical Implications
Ahmed Elamin, Mustafa Abdimalik, Mohanad Abdelrahim, et al.
European Cardiology Review 2025;20:e34.
Decoding Immune Influence: A Mendelian Randomisation Study on Dilated Cardiomyopathy
Wei Gao, Hui Wang, Jian-long Wang, et al.
European Cardiology Review 2025;20:e33.
Patient Perspective: How Patient Values Set a Historic Benchmark for the ESC/EACTS Guidelines 2025 for the Management of Valvular Heart Disease
Benoit Mores
European Cardiology Review 2025;20:e32.
Ethical Challenges in Scientific Publishing: Insights from New Fireside Chats at the 2025 European Society of Cardiology Congress
Alessandro Mugelli
European Cardiology Review 2025;20:e31.
Arterial Hypertension: Highlights from the European Society of Cardiology 2025 Congress
Maria Lorenza Muiesan, Matteo Lemoli
European Cardiology Review 2025;20:e30.
Innovation and Development in Polymer Heart Valves: A New Era of Transcatheter Aortic Valve Replacement
Yu Mao, Fengkai Liu, Xi Chen, et al.
European Cardiology Review 2025;20:e29.
Obesity and Chronic Kidney Disease: The Dual Epidemic in Cardiovascular Health
Christopher Henry Grant, Samira Bell
European Cardiology Review 2025;20:e28.
Follow us on social
International Society of Cardiovascular Pharmacotherapy
Via Rotondello 16, 6517 Arbedo, Switzerland